This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, S. Articles by Furmaniak, J. Search for Related Content PubMed PubMed Citation Articles by Chen, S. Articles by Furmaniak, J.

Analysis of Autoantibody Epitopes on Steroid 21-Hydroxylase Using a Panel of Monoclonal Antibodies¹

FIRS Laboratories, RSR Limited (S.C., J.S., L.P., J.F.S., H.T., V.P., S.R., M.P., B.R.S., J.F.), Llanishen, Cardiff, Wales, United Kingdom CF4 5DU; Istituto di Semeiotica Medica, University of Padua (C.B., M.V.), Padua, Italy; and Department of Medicine, University of Wales College of Medicine (S.C., J.S., H.T., B.R.S., J.F.), Heath Park, Cardiff, Wales, United Kingdom CF4 4XN

Address all correspondence and requests for reprints to: J. Furmaniak, FIRS Laboratories, RSR Limited, Parc Ty Glas, Llanishen, Cardiff, Wales, United Kingdom CF4 5DU.

A panel of five mouse monoclonal antibodies (MAbs) to human recombinant steroid 21-hydroxylase (21-OH) were produced, characterized, and used to study the interaction of 21-OH autoantibodies (AAbs) with different epitopes on human 21-OH. AAbs in patients with isolated autoimmune Addison’s disease, autoimmune polyglandular syndromes types I and II, and 21-OH antibody-positive patients without overt Addison’s disease (25 patients in total) were studied. Four MAbs were IgG1 subclass, one was IgG2a, and all had light chains. The affinities of four of the antibodies were in the range 2.0 x 10⁸ M^-1 to 7.0 x 10⁸ M^-1, and the affinity of the other was 2.3 x 10⁷ M^-1. 21-OH MAbs did not cross-react with 17-hydroxylase (17-OH) or P450 side chain cleavage enzyme. Studies using a series of 21-OH fragments allowed the identification of short stretches of amino acids (AA) that were involved in forming the MAb binding sites. AA 391–405, defined as epitope region (ER) 1, were found to be important for binding of M21-OH1 and M21-OH2, AA 406–411 (ER2) were important for M21-OH3 and M21-OH4 binding, and AA 335–339 (ER3) for M21-OH5 binding. In addition, MAb Fab or F(ab')₂ fragments were used to study 21-OH AAb epitopes in competition experiments. These investigations demonstrated that 21-OH AAbs recognize similar epitopes to the MAbs, with ER2 and ER3 being part of two distinct major epitopes, and ER 1 being part of a minor epitope. Mixtures of M21-OH antibody Fab or F(ab')₂ fragments caused almost complete inhibition (80%–95%) of AAb binding in 24 out of 25 sera, and in the case of the remaining serum, the effect was marked but incomplete (67% inhibition). There were no major differences between the binding characteristics of AAbs from patients with different forms of autoimmune adrenal disease. All five 21-OH MAbs reacted with human adrenal tissue in an immunofluorescence test, but only M21-OH1 and M21-OH2 reacted with bovine adrenal tissue in these experiments. None of the MAbs reacted with human ovarian tissue in an immunofluorescence test. Overall, these studies indicate that 21-OH AAbs bind to at least three different epitopes in the C-terminal part of 21-OH, and two of these epitopes appear to be human 21-OH specific.

This article has been cited by other articles:

				R. N. Miguel, S. Chen, L. Nikfarjam, S. Kominami, B. Carpenter, C. Dal Pra, C. Betterle, R. Zanchetta, T. Nakamatsu, M. Powell, et al. Analysis of the interaction between human steroid 21-hydroxylase and various monoclonal antibodies using comparative structural modelling Eur. J. Endocrinol., December 1, 2005; 153(6): 949 - 961. [Abstract] [Full Text] [PDF]

				L Nikfarjam, S Kominami, T Yamazaki, S Chen, R Hewer, C Dal Pra, T Nakamatsu, C Betterle, R Zanchetta, B Rees Smith, et al. Mechanism of inhibition of cytochrome P450 C21 enzyme activity by autoantibodies from patients with Addison's disease Eur. J. Endocrinol., January 1, 2005; 152(1): 95 - 101. [Abstract] [Full Text] [PDF]

				C. Betterle, C. Dal Pra, F. Mantero, and R. Zanchetta Autoimmune Adrenal Insufficiency and Autoimmune Polyendocrine Syndromes: Autoantibodies, Autoantigens, and Their Applicability in Diagnosis and Disease Prediction Endocr. Rev., June 1, 2002; 23(3): 327 - 364. [Abstract] [Full Text] [PDF]

				C. A. Stratakis, T. Papageorgiou, A. Premkumar, S. Pack, L. S. Kirschner, S. E. Taymans, Z. Zhuang, W. H. Oelkers, and J. A. Carney Ovarian Lesions in Carney Complex: Clinical Genetics and Possible Predisposition to Malignancy J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4359 - 4366. [Abstract] [Full Text]